|
Prior to joining Tercica in 2003, Andrew Grethlein served at Athena Neurosciences and Élan, most recently as senior director and site head, South San Francisco Pharmaceutical Operations. In this capacity, Dr. Grethlein held responsibility for commercial GMP manufacturing operations for MyoBloc?(Botulinum Toxin Type B) Injectable Solution. While at Athena and Élan, Dr. Grethlein held positions of responsibility for clinical manufacturing, facility design, construction, and start-up, and manufacturing operations in support of product licensure in the United States and EU. He also served in various engineering capacities for non-profit research and business development corporation Michigan Biotechnology Institute and its subsidiary Grand River Technologies, Inc. Dr. Grethlein earned his BS in Biology from Bates College and an MS and PhD in Chemical Engineering from Michigan State University. | 